Biomedical Chromatography · 2012 · 94 citations · 51 references
PharmacyOncologyPharmacologyCancer PharmacologyChemotherapyPharmacokinetics Of Anticancer AgentsBioanalytical Method ValidationChemotherapy Toxicity ManagementDrug DispositionOncology PharmacologyPharmacokinetics Of Anticancer DrugsToxicity Management5-Fluorouracil Therapy5-Fluorouracil TreatmentAssayAssay SpecificityDihydropyrimidine Dehydrogenase TestingDrug Toxicity PredictionQuantification Of AnalytesTherapeutic Drug Monitoring Biomarkers
The chemotherapeutic drug 5-fluorouracil (5-FU) is widely used for treating solid tumors. Response to 5-FU treatment is variable with 10-30% of patients experiencing serious toxicity partly explained by reduced activity of dihydropyrimidine dehydrogenase (DPD). DPD converts endogenous uracil (U) into 5,6-dihydrouracil (UH(2) ), and analogously, 5-FU into 5-fluoro-5,6-dihydrouracil (5-FUH(2) ). Combined quantification of U and UH(2) with 5-FU and 5-FUH(2) may provide a pre-therapeutic assessment of DPD activity and further guide drug dosing during therapy. Here, we report the development of a liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of U, UH(2) , 5-FU and 5-FUH(2) in human plasma. Samples were prepared by liquid-liquid extraction with 10:1 ethyl acetate-2-propanol (v/v). The evaporated samples were reconstituted in 0.1% formic acid and 10 μL aliquots were injected into the HPLC system. Analyte separation was achieved on an Atlantis dC(18) column with a mobile phase consisting of 1.0 mm ammonium acetate, 0.5 mm formic acid and 3.3% methanol. Positively ionized analytes were detected by multiple reaction monitoring. The analytical response was linear in the range 0.01-10 μm for U, 0.1-10 μm for UH(2) , 0.1-75 μm for 5-FU and 0.75-75 μm for 5-FUH(2) , covering the expected concentration ranges in plasma. The method was validated following the FDA guidelines and applied to clinical samples obtained from ten 5-FU-treated colorectal cancer patients. The present method merges the analysis of 5-FU pharmacokinetics and DPD activity into a single assay representing a valuable tool to improve the efficacy and safety of 5-FU-based chemotherapy.
51
Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds
Charles Heidelberger, P Danneberg, Dorothy Mooren et al. · Nature · 1957 · 1.6K citations
Systemic Therapy for Colorectal Cancer
Jeffrey A. Meyerhardt, Robert J. Mayer · New England Journal of Medicine · 2005 · 1.1K citations
Medicine, Oncology, Pharmacology +17
Systemic Therapy for Colorectal Cancer
Anna M. Varghese · DeckerMed CGSO Case-Based Reviews · 2019 · 883 citations
Medicine, Oncology, Pharmacology +17
Population study of dihydropyrimidine dehydrogenase in cancer patients.
M C Etienne, J.-L. Lagrange, O. Dassonville et al. · Journal of Clinical Oncology · 1994 · 432 citations
Medicine, Oncology, Pharmacology +15